Nanobiotix Aktie [WKN DE: A1J7EB / ISIN: FR0011341205]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Nanobiotix SA

26.05.21		NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference (Businesswire)
25.05.21		Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board (Businesswire)
12.05.21		Nanobiotix to Present at the UBS Global Healthcare Virtual Conference (Businesswire)
11.05.21		NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets (Businesswire)
29.04.21		NANOBIOTIX Announces First Quarter Operational and Financial Updates (Businesswire)
12.04.21		Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021 (Businesswire)
08.04.21		NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F (Businesswire)
17.03.21		NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress (Businesswire)
04.03.21		NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration (Businesswire)
03.03.21		NANOBIOTIX to Present at the H.C. Wainwright Global Life Sciences Conference (Businesswire)
26.02.21		NANOBIOTIX 2020 Q4 and Annual Revenues (Businesswire)
28.01.21		NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer (Businesswire)
25.01.21		Nanobiotix Subsidiary Curadigm Secures New Collaboration Agreement With Sanofi Focused on Gene Therapy Pipeline (Businesswire)
15.01.21		Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021 (Businesswire)
08.01.21		Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering (Businesswire)
18.12.20		Nanobiotix Announces Closing of Underwriters’ Option to Purchase Additional ADSs (Businesswire)
15.12.20		NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million (Businesswire)
11.12.20		NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market (Businesswire)
10.12.20		NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range (Businesswire)
07.12.20		Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing (Businesswire)
07.12.20		NANOBIOTIX Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing (Businesswire)
20.11.20		NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States (Businesswire)
17.11.20		Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer (Businesswire)
12.11.20		NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy (Businesswire)
10.11.20		NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3 (Businesswire)
26.10.20		NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020 (Businesswire)
23.10.20		Nanobiotix Announces Third Quarter 2020 Revenue (Businesswire)
20.10.20		NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting (Businesswire)
13.10.20		NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA (Businesswire)
04.09.20		NANOBIOTIX Announces Half-year Financial Statements as at June 30, 2020 (Businesswire)
28.07.20		Nanobiotix Successfully Raises Approximately €20 (us$24) Million in Placement of Ordinary New Shares With Us and European Investors (Businesswire)
27.07.20		Nanobiotix Launches a Capital Increase by Means of an Accelerated Bookbuild Offering (Businesswire)
17.07.20		Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 (Businesswire)
17.06.20		Nanobiotix Receives Feedback From US FDA to Advance Phase III Head and Neck Cancer Study Design and CMC Development Plan for NDA (Businesswire)
10.06.20		NANOBIOTIX Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Therapeutics (Businesswire)
10.06.20		Curadigm Announces Publication of Results Using Proprietary Nanoprimer to Improve RNA Therapeutics in Collaboration With the Langer Lab (Businesswire)
08.06.20		Nanobiotix Secures €10M in Non-Dilutive Financing (Businesswire)
29.05.20		Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020 (Businesswire)
06.05.20		NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA (Businesswire)
30.04.20		NANOBIOTIX Announces First Quarter 2020 Revenues (Businesswire)
21.04.20		NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis (Businesswire)
17.03.20		NANOBIOTIX 2019 Annual Results (Businesswire)
09.03.20		Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration (Businesswire)
28.02.20		Nanobiotix 2019 Q4 and Annual Revenues (Businesswire)
07.01.20		NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update (Businesswire)
25.10.19		NANOBIOTIX Announces Third Quarter 2019 Revenue (Businesswire)
18.09.19		Phase I Study Results Show First-in-class NBTXR3 Could Present as a Valuable Option for Patients With Hepatocellular Carcinoma or Liver Metastasis (Businesswire)
04.09.19		Nanobiotix Announces Half-year Financial Statements as of June 30, 2019 (Businesswire)
09.07.19		Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology (GlobeNewswire)
01.07.19		Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval (GlobeNewswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 10:07
Kaufwert:	EUR
	Hinzufügen Speichern